文献速递肝病

LITMUS联盟中非酒精性脂肪性肝病与非酒精性脂肪性肝炎生物标志物资格认定——经验教训

NAFLD and NASH biomarker qualification in the LITMUS consortium - Lessons learned.
PubMed 文献 · J Hepatol · 2022-12-14

本文阐述生物标志物如何加速药物开发,并回顾由欧盟IMI2资助的LITMUS联盟在非酒精性脂肪性肝病和非酒精性脂肪性肝炎患者生物标志物资格认定方面与美国和欧盟监管机构多次互动中获得的经验教训,强调与科学界共享此类互动知识对提高相关生物标志物资格认定机会至关重要。

要点

  • LITMUS联盟就非酒精性脂肪性肝病和非酒精性脂肪性肝炎生物标志物资格认定与美国和欧盟监管机构进行了多次互动。
  • 与科学界共享监管互动的知识对提高相关生物标志物资格认定机会至关重要。
  • 获得资格认定的生物标志物可使各方在共同框架下做出决策。

核心结论

  • 与科学界共享监管互动的知识对提高相关生物标志物资格认定机会至关重要,这些生物标志物可能加速药物开发并惠及不同疾病适应症的患者。
  • 获得资格认定的生物标志物使各方能在共同框架下做出决策。

研究设计与样本

  • 本文为综述,由欧盟IMI2资助的LITMUS联盟回顾其与美国和欧盟监管机构就非酒精性脂肪性肝病和非酒精性脂肪性肝炎生物标志物资格认定进行的多次互动经验。

主要发现

  • 目前通过监管机构生物标志物资格认定途径获批的生物标志物很少。
  • LITMUS联盟已就非酒精性脂肪性肝病和非酒精性脂肪性肝炎生物标志物资格认定与美国和欧盟监管机构进行了多次互动。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Biomarkers have the potential to accelerate drug development, as early indicators of improved clinical response, to improve patient safety, and for personalised medicine. However, few have been approved through the biomarker qualification pathways of the regulatory agencies. This paper outlines how biomarkers can accelerate drug development, and reviews the lessons learned by the EU IMI2-funded LITMUS consortium, which has had several interactions with regulatory agencies in both the US and EU regarding biomarker qualification in patients with non-alcoholic fatty liver disease and non-alcoholic steatohepatitis. Sharing knowledge of such interactions with the scientific community is of paramount importance to increase the chances of qualification of relevant biomarkers that may accelerate drug development, and thereby help patients, across disease indications. A qualified biomarker enables a decision to be made that all understand and support in a common framework.

来源:J Hepatol,查看原文。版权归原作者所有。

引用

  1. Rasmussen DGK, Anstee QM, Torstenson R, et al. NAFLD and NASH biomarker qualification in the LITMUS consortium - Lessons learned. J Hepatol. 2022. PMID: 36526000. doi:10.1016/j.jhep.2022.11.028

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。